Andrew Nixon, Boehringer Ingelheim's global head of biotherapeutics discovery
November 29, 2023 02:29 PM EST
Deals
AI

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Ryan Cross

Senior Science Correspondent

Boehringer In­gel­heim is the lat­est drug­mak­er turn­ing to gen­er­a­tive AI for help in mak­ing med­i­cines. On Tues­day, the Ger­man phar­ma gi­ant

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times